- Home
- ISPR vs GLSI Comparison
ISPR vs GLSI Comparison
Compare ISPR & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPR
- GLSI
- Stock Information
- Founded
- ISPR 2019
- GLSI 2006
- Country
- ISPR United States
- GLSI United States
- Employees
- ISPR N/A
- GLSI N/A
- Industry
- ISPR Medicinal Chemicals and Botanical Products
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- ISPR Health Care
- GLSI Health Care
- Exchange
- ISPR Nasdaq
- GLSI Nasdaq
- Market Cap
- ISPR 152.0M
- GLSI 134.6M
- IPO Year
- ISPR 2023
- GLSI 2020
- Fundamental
- Price
- ISPR $3.06
- GLSI $11.48
- Analyst Decision
- ISPR Strong Buy
- GLSI Strong Buy
- Analyst Count
- ISPR 2
- GLSI 1
- Target Price
- ISPR $10.00
- GLSI $39.00
- AVG Volume (30 Days)
- ISPR 47.6K
- GLSI 43.7K
- Earning Date
- ISPR 09-19-2025
- GLSI 08-14-2025
- Dividend Yield
- ISPR N/A
- GLSI N/A
- EPS Growth
- ISPR N/A
- GLSI N/A
- EPS
- ISPR N/A
- GLSI N/A
- Revenue
- ISPR $144,700,345.00
- GLSI N/A
- Revenue This Year
- ISPR N/A
- GLSI N/A
- Revenue Next Year
- ISPR $35.39
- GLSI N/A
- P/E Ratio
- ISPR N/A
- GLSI N/A
- Revenue Growth
- ISPR N/A
- GLSI N/A
- 52 Week Low
- ISPR $2.09
- GLSI $8.06
- 52 Week High
- ISPR $7.79
- GLSI $16.50
- Technical
- Relative Strength Index (RSI)
- ISPR 66.49
- GLSI 48.08
- Support Level
- ISPR $2.74
- GLSI $11.35
- Resistance Level
- ISPR $3.43
- GLSI $12.07
- Average True Range (ATR)
- ISPR 0.19
- GLSI 0.57
- MACD
- ISPR 0.05
- GLSI -0.12
- Stochastic Oscillator
- ISPR 82.67
- GLSI 8.78
About ISPR Ispire Technology Inc.
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping in the United States, Europe, Canada, and South Africa.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.